The observed trend for increased levels of D in CSF in participants with higher levels baseline CSF NfL highlights how factors relevant to AD severity and neurodegenerative disease progression should be considered in regard to therapeutic effect and efficacy within and across individuals. This evidence concerns the gene NEFL and neurodegenerative disease.